---
layout: default
title: Fulvestrant
parent: Model Prediction Only (L5)
nav_order: 742
evidence_level: L5
indication_count: 10
---

# Fulvestrant
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Fulvestrant: From Breast Cancer to HIV Infectious Disease

## One-Sentence Summary

Fulvestrant is an injectable estrogen receptor antagonist and degrader, used for hormone receptor-positive breast cancer.
The TxGNN model predicts it may be effective for **HIV infectious disease**, but there are currently **0 registered clinical trials** and **no directly relevant publications** supporting this direction. The prediction rests on the model alone.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Hormone receptor-positive breast cancer (the US licence records contain no indication text; this comes from the drug's known use and the related trial context) |
| Predicted New Indication | HIV infectious disease |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the input. Based on known information, fulvestrant is an estrogen receptor antagonist and degrader. Its efficacy in hormone receptor-positive breast cancer is established, but that mechanism has no known link to HIV.

The prediction is best read as a graph-based signal from the TxGNN knowledge graph, not a mechanistic hypothesis. Two other predictions support this reading. Simian immunodeficiency virus infection and feline acquired immunodeficiency syndrome received near-identical scores of 99.83%, which suggests they are correlated with the HIV prediction through disease-node similarity. Estrogen receptor antagonism has no established role in HIV pathogenesis, so the prediction needs independent mechanistic and experimental support before it can be treated as credible.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [40343334](https://pubmed.ncbi.nlm.nih.gov/40343334/) | 2025 | Multi-cohort cross-omics analysis | Research Square | Systems biology study of HTLV-1-associated myelopathy, a neuroinflammatory disease caused by a different retrovirus. It is not an HIV study, and no fulvestrant data are evident from the title or abstract. |

This is the only retrieved item, and it does not support the predicted indication.

## US Market Information

The licence records contain no approved indication text. Of the 20 licences, the 5 main ones are listed below.

| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---------|------|------|-----------|
| NDA210326 | Fulvestrant | Injection, solution | Fresenius Kabi USA, LLC |
| ANDA215077 | Fulvestrant | Injection | Alembic Pharmaceuticals Inc. |
| ANDA211422 | Fulvestrant | Injection, solution | Avenacy, Inc. |
| ANDA205935 | Fulvestrant | Injection | Sandoz Inc |
| ANDA215077 | Fulvestrant | Injection | BluePoint Laboratories. |

All listed forms are injectables.

## Cytotoxicity

| Item | Content |
|------|------|
| Cytotoxicity Classification | Endocrine therapy (estrogen receptor antagonist and degrader), not a conventional cytotoxic agent |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |

## Safety Considerations

Please refer to the package insert for safety information. No drug-drug interaction records were found for this drug.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The HIV prediction has a high model score, but it has no clinical trials, no relevant literature and no plausible mechanism linking estrogen receptor antagonism to HIV. Evidence is at L5 (model prediction only), so the prediction is not ready for development.

**To proceed, the following is needed:**
- Fulvestrant's mechanism of action data, plus a mechanistic hypothesis for the HIV link.
- Package insert warnings and contraindications, which are needed before any safety screening.
- Supporting preclinical evidence, such as in vitro or animal data on fulvestrant in HIV or related lentiviral models.
- A curated literature search, since the one retrieved paper concerns HTLV-1 rather than HIV.

Among the other predictions, rheumatoid arthritis (score 99.58%) reached L4. Its preclinical estrogen-signaling data point in ambiguous directions, and it is best treated as a research question.

*This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any use.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

